There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (CLSD) and Immune Design (IMDZ) with bullish sentiments.
Clearside Biomedical (CLSD)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical today and set a price target of $5. The company’s shares opened today at $1.72, close to its 52-week low of $0.99.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.4% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Clearside Biomedical has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Immune Design (IMDZ)
In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Immune Design. The company’s shares opened today at $5.82, equals to its 52-week high of $5.82.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.1% and a 43.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Immune Design has an analyst consensus of Moderate Buy, with a price target consensus of $5.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
